Medical Dosimetry
Volume 32, Issue 2 , Pages 71-79 , Summer 2007

Investigation of Linac-Based Image-Guided Hypofractionated Prostate Radiotherapy

Presented in part at the 47th Annual Meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO); Denver, CO, October 16–20, 2005.

,Accepted 11 January 2007.

References 

  1. King CR, Cotrutz C, et al. Hypo-fractionated radiotherapy for localized prostate cancer: Therapeutic rationale and feasibility of the CyberKnife. In:  Mould RF editors. Robot Radiosurgery. Vol. 1:Sunnyvale: The CyberKnife Society Press; 2005;p. 315–323
  2. King CR, Lehmann J, Adler JR, et al. CyberKnife radiotherapy for localized prostate cancer: Rationale and technical feasibility. Technol. Cancer Res. Treat. 2003;2:25–30
  3. King CR, Presti J, Harcharan G, et al. Stanford University IRB Panel Hypofractionated Radiotherapy for Localized Prostate Cancer. 2004;Vol. Protocol ID 79432
  4. King CR, Fowler JF. A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 2001;51:213–214
  5. Fowler J, Chappell R, Ritter M. Is alpha/beta for prostate tumors really low?. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 2001;50:1021–1031
  6. Brenner DJ. Toward optimal external-beam fractionation for prostate cancer. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 2000;48:315–316
  7. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 1999;43:1095–1101
  8. Brenner DJ, Martinez AA, Edmundson GK, et al. Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 2002;52:6–13
  9. Lloyd-Davis RW, Collins CD, Swan AV. Carcinoma of prostate treated by a radical external beam radiotherapy using hypofractionation: 22 years experience (1962–1984). Urology. 1990;36:107–111
  10. Kupelian PA, Reddy CA, Klein EA, et al. Short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. [see comment] Int. J. Radiat. Oncol. Biol. Phys. 2001;51:988–993
  11. Koukourakis M, Touloupidis S, Manavis J, et al. Conformal hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC) for high risk prostatic carcinoma: Rationale, technique and early experience. Anticancer Res. 2004;24:3239–3243
  12. Martinez AA, Pataki I, Edmundson G, et al. Phase II prospective study of the use of conformal high-dose-rate brachytherapy as monotherapy for the treatment of favorable stage prostate cancer: A feasibility report. Int. J. Radiat. Oncol. Biol. Phys. 2001;49:61–69
  13. Hall EJ. Radiobiology for the Radiologist. 4th ed.. Philadelphia: J.B. Lippincott Company; 1994;
  14. Fowler JF, Ritter MA, Chappell RJ, et al. What hypofractionated protocols should be tested for prostate cancer?. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:1093–1104
  15. Byrne TE. A review of prostate motion with considerations for the treatment of prostate cancer. Med. Dosim. 2005;30:155–161
  16. Malone S, Crook JM, Kendal WS, et al. Respiratory-induced prostate motion: Quantification and characterization. Int. J. Radiat. Oncol. Biol. Phys. 2000;48:105–109
  17. Kitamura K, Shirato H, Seppenwoolde Y, et al. Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:1117–1123
  18. Bayley AJ, Catton CN, Haycocks T, et al. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer. Radiother. Oncol. 2004;70:37–44
  19. Kitakura K, Shirato H, Shinohara K, et al. Reduction in acute morbidity using hypofractionated intensity-modulated radiation therapy assisted with a fluoroscopic real-time tumor-tracking system for prostate cancer: Preliminary results of a phase I/II study. Cancer J. 2003;9:268–276
  20. Cheung P, Sixel K, Morton G, et al. Individualized planning target volumes for intrafraction motion during hypofractionated intensity-modulated radiotherapy boost for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005;62:418–425
  21. Amer AM, Mott J, MacKay RI, et al. Prediction of the benefits from dose-escalated hypofractionated intensity-modulated radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;56:199–207
  22. Song W, Schaly B, Gauman G, et al. Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Med. Phys. 2005;32:2193–2203
  23. Craig T, Moiseenko V, Battista J, et al. The impact of geometric uncertainty on hypofractionated external beam radiation therapy of prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2003;57:833–842
  24. Huang E, Dong L, Chandra A, et al. Intrafraction prostate motion during IMRT for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:261–268
  25. Nederveen AJ, van der Heide UA, Dehnad H, et al. Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int. J. Radiat. Oncol. Biol. Phys. 2002;53:206–214
  26. Britton KR, Takai Y, Mitsuya M, et al. Evaluation of inter- and intrafraction organ motion during intensity modulated radiation therapy (IMRT) for localized prostate cancer measured by a newly developed on-board image-guided system. Radiat. Med. 2005;23:14–24

PII: S0958-3947(07)00004-0

doi: 10.1016/j.meddos.2007.01.004

Medical Dosimetry
Volume 32, Issue 2 , Pages 71-79 , Summer 2007

Article Tools

* Image Usage & Resolution